Analysis of Biapenem for the treatment of respiratory infections in very elderly patients
10.3760/cma.j.issn.0254-9026.2022.12.016
- VernacularTitle:比阿培南治疗高龄老年患者呼吸系统感染的分析
- Author:
Yuanchao ZHU
1
;
Qi ZOU
;
Xin HU
Author Information
1. 北京医院药学部 国家老年医学中心 中国医学科学院老年医学研究院 北京市药物临床风险与个体化应用评价重点实验室(北京医院)，北京 100730
- Keywords:
Anti-bacterial agents;
Respiratory tract infections;
Clinical efficacy;
Clinical safety
- From:
Chinese Journal of Geriatrics
2022;41(12):1489-1493
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To evaluate the efficacy and safety of Biapenem in very elderly patients(≥85 years old)with respiratory infections, and to provide a basis for rational use of Biapenem.Methods:A retrospective study was conducted on patients ≥85 years old, who had received Biapenem and undergone relevant laboratory tests from January 2016 to December 2017.Results:A total of 194 patients, with an average age of (88.5±3.1)years were enrolled.The rate of clinical effectiveness for infection treatment was 66.5%(129/194).Logistic regression analysis showed that blood urea nitrogen(BUN)≥8.2 mmol/L( OR=2.404, 95% CI: 1.425-4.065, P=0.001)and Biapenem monotherapy( OR=1.995, 95% CI: 1.175-3.386, P=0.006)were independent risk factors for treatment failure, while other factors, such as underlying diseases, body temperature, previous drug use, alanine aminotransferase levels and aspartate aminotransferase levels, showed no clear association with clinical outcomes.BUN showed significant elevations from pretreatment(8.6 ± 5.1)mmol/L to post-treatment(10.3 ± 9.8)mmol/L( t=-3.362, P=0.001).Adverse drug reactions were observed in 11.9%(23/194)patients, and all these were mild or intermediate. Conclusions:Biapenem is efficacious and safe when used for the treatment of respiratory infections in very elderly patients, and BUN level monitoring during treatment is recommended.
